Comparative Pharmacology
Head-to-head clinical analysis: FAMOTIDINE CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE versus LAX LYTE WITH FLAVOR PACKS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FAMOTIDINE CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE versus LAX LYTE WITH FLAVOR PACKS.
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE vs LAX-LYTE WITH FLAVOR PACKS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Famotidine is a competitive histamine H2-receptor antagonist that inhibits gastric acid secretion by blocking H2 receptors on parietal cells. Calcium carbonate and magnesium hydroxide act as antacids, neutralizing gastric acid via chemical neutralization.
Osmotic laxative: polyethylene glycol (PEG) retains water in the intestinal lumen, increasing stool volume and stimulating peristalsis. Electrolytes (sodium, potassium, chloride, bicarbonate) prevent electrolyte depletion.
1 tablet (famotidine 10 mg, calcium carbonate 800 mg, magnesium hydroxide 165 mg) orally once or twice daily as needed for heartburn; maximum 2 tablets in 24 hours.
Oral: 1 to 2 packets (4 to 8 g of polyethylene glycol 3350) dissolved in 4 to 8 ounces of water once daily, as needed for constipation. Maximum: 2 packets per day.
None Documented
None Documented
Famotidine: 2.5-3.5 hours (prolonged in renal impairment, up to 20 hours when CrCl <10 mL/min).
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged in renal impairment (up to 20 hours).
Famotidine: renal (65-70% unchanged), biliary/fecal (30-35%). Calcium carbonate: feces (unabsorbed calcium), urine (absorbed). Magnesium hydroxide: feces (unabsorbed magnesium), urine (absorbed).
Primarily renal (30-50% unchanged) and biliary/fecal (50-70% as inactive metabolites).
Category A/B
Category C
Antacid / Laxative
Laxative